42
Participants
Start Date
April 8, 2025
Primary Completion Date
April 30, 2027
Study Completion Date
April 30, 2028
Vebreltinib combined with Furmonertinib
Vebreltinib 100mg/1500mg/200mg oral twice daily combined with Furmonertinib 80mg oral once daily
Vebreltinib combined with Furmonertinib
Vebreltinib 100mg/1500mg/200mg oral twice daily combined with Furmonertinib 80mg oral once daily. Based on the safety data from the completed dose cohorts, the investigators will involve the selection of 1-2 dose cohorts for further study. Approximately 10 additional subjects will be enrolled in the selected dose expansion cohort to determine the recommended dose for Phase II clinical trials.
Vebreltinib combined with Furmonertinib
RP2D of Vebreltinib as determined during Phase Ib oral twice daily combined with Furmonertinib 80mg oral once daily
RECRUITING
Peking University Cancer Hospital & Institute, Beijing
NOT_YET_RECRUITING
Ordos Central Hospital, Neimeng
NOT_YET_RECRUITING
Peking University Cancer Hospital (Inner Mongolia Campus), Neimeng
NOT_YET_RECRUITING
Affiliated Hospital of Hebei University, Baoding
RECRUITING
Baotou Cancer Hospital, Baotou
NOT_YET_RECRUITING
Beijing Chest Hospital, Capital Medical University, Beijing
NOT_YET_RECRUITING
Beijing Daxing District People's Hospital, Beijing
NOT_YET_RECRUITING
Peking Union Medical College Hospital, Beijing
NOT_YET_RECRUITING
Peking University People's Hospital, Beijing
NOT_YET_RECRUITING
Peking University Third Hospital, Beijing
NOT_YET_RECRUITING
The Second Hospital of Dalian Medical University, Dalian
NOT_YET_RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Peking University Cancer Hospital & Institute
OTHER